Overexpression of Ccnd1 is strongly correlated to decreased progression free survival (36) and loss of Cdkn2a through mutation or hypermethylation has also been shown in human ovarian carcinomas (35, 37–39). Here, CDKN2A is linked to ovarian carcinoma.